Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
Uplizna is currently approved in the U.S., Europe and Canada, among others, for a rare, severe, neuroinflammatory disease ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Amgen latest news, photos, videos, breaking news, special reports, blogs, and updates from Business Insider India ...
Uplizna therapy reaches main goal in Phase 3 trial for IgG4-RD, cutting the risk of flare by 87% with no new safety events.
The world's first human trial of a drug designed to regenerate real teeth is set to commence in jus… ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
FDA staff also said vaccine makers developing the new booster shots may need to consider targeting one of the JN.1 ...
The US Food and Drug Administration approved Cambridge, Massachusetts-based Moderna’s vaccine for a respiratory virus which ...